iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Lupin Ltd News Today

1,986.7
(1.63%)
Jul 4, 2025|10:09:59 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Company

Sectoral

Lupin gets USFDA approval for post-eye surgery drug

This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.

2 Jul 2025|11:27 AM
Top Stocks for Today - 2nd July 2025

Here are some of the stocks that may see significant price movement today: Godrej Properties, SBI Cards, Hyudai India, etc.

2 Jul 2025|06:39 AM
Lupin Expands US Presence with Launch of Prucalopride Tablets

The tablets will be made at the company’s Goa facility, a site that has previously cleared global regulatory inspections and supports Lupin’s key exports.

27 Jun 2025|10:48 AM
Lupin Expands to China with Tiotropium Inhaler Deal Amid Rising COPD Cases

The company said this deal fits into its larger strategy of expanding respiratory therapies beyond its home markets.

16 Jun 2025|02:08 PM
Lupin inks licensing pact with SteinCares for biosimilar

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America.

27 May 2025|10:29 AM
Top Stocks for Today - 27th May 2025

Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.

27 May 2025|06:36 AM
Lupin Secures USFDA Approval for Tolvaptan Tablets

The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.

24 Apr 2025|09:39 PM
Lupin Gets USFDA Nod for Nagpur Injectable Plant After Clean Inspection

The clearance is on the back of a four-day USFDA inspection between June 10 and June 13, 2024.

18 Apr 2025|12:29 AM
Lupin Acquires UK’s Renascience Pharma for ₹135 Crore

The acquisition enhances Lupin’s portfolio of branded medicines and is aimed at furthering the company’s commitment to providing affordable and sustainable healthcare solutions.

4 Apr 2025|01:30 PM
Lupin Expands US Portfolio with USFDA Approval for Amifampridine

Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.

17 Mar 2025|10:28 PM
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.